1.47
Galmed Pharmaceuticals Ltd stock is traded at $1.47, with a volume of 40,540.
It is up +3.52% in the last 24 hours and down -2.65% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.42
Open:
$1.43
24h Volume:
40,540
Relative Volume:
0.21
Market Cap:
$8.05M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.4509
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
-8.70%
1M Performance:
-2.65%
6M Performance:
+11.36%
1Y Performance:
-61.82%
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GLMD
Galmed Pharmaceuticals Ltd
|
1.47 | 7.78M | 0 | -6.91M | -6.14M | -3.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
Feb-04-20 | Initiated | Craig Hallum | Buy |
Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
Dec-02-19 | Initiated | Canaccord Genuity | Buy |
Dec-12-18 | Initiated | B. Riley FBR | Buy |
Aug-02-18 | Reiterated | Maxim Group | Buy |
Jul-13-18 | Initiated | Stifel | Buy |
Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
Nov-15-17 | Initiated | ROTH Capital | Buy |
Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
Jul-31-17 | Reiterated | Maxim Group | Buy |
Aug-01-16 | Reiterated | Maxim Group | Buy |
Jul-06-16 | Resumed | ROTH Capital | Buy |
Mar-28-16 | Resumed | H.C. Wainwright | Buy |
Jun-23-15 | Initiated | H.C. Wainwright | Buy |
May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
What data driven models say about Galmed Pharmaceuticals Ltd.’s future2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
How Galmed Pharmaceuticals Ltd. stock reacts to inflationary pressures2025 Key Highlights & Smart Money Movement Alerts - newser.com
Is Galmed Pharmaceuticals Ltd. a candidate for recovery playTreasury Yields & Daily Market Momentum Tracking - newser.com
Can volume confirm reversal in Galmed Pharmaceuticals Ltd.Inflation Watch & Verified Technical Signals - newser.com
Why Galmed Pharmaceuticals Ltd. stock remains on buy listsProfit Target & AI Powered Market Entry Strategies - newser.com
What institutional flow reveals about Galmed Pharmaceuticals Ltd.2025 Price Targets & Community Consensus Picks - newser.com
Building trade automation scripts for Galmed Pharmaceuticals Ltd.July 2025 Patterns & Community Consensus Trade Alerts - newser.com
Is Galmed Pharmaceuticals Ltd. stock a top momentum playJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Will Galmed Pharmaceuticals Ltd. benefit from macro trendsJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
Galmed Pharmaceuticals Ltd.’s volatility index tracking explainedWeekly Trade Summary & Community Consensus Trade Signals - newser.com
What drives Galmed Pharmaceuticals Ltd stock priceMid Cap Growth Trends & Investment Portfolio Recommendations - earlytimes.in
Understanding Galmed Pharmaceuticals Ltd.’s price movementQuarterly Market Review & Comprehensive Market Scan Reports - newser.com
How Galmed Pharmaceuticals Ltd. stock reacts to Fed rate cuts2025 Market Trends & Community Consensus Stock Picks - newser.com
Weiss Ratings Reiterates “Sell (E+)” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
News impact scoring models applied to Galmed Pharmaceuticals Ltd.Weekly Trading Summary & Verified Momentum Stock Watchlist - newser.com
Will Galmed Pharmaceuticals Ltd. (GPH) stock outperform benchmarksShort Setup & Advanced Technical Analysis Signals - newser.com
What the charts say about Galmed Pharmaceuticals Ltd. todayQuarterly Trade Review & Breakout Confirmation Trade Signals - newser.com
Galmed Pharmaceuticals Ltd. stock prediction for this weekJuly 2025 Breakouts & Reliable Trade Execution Plans - newser.com
Combining machine learning predictions for Galmed Pharmaceuticals Ltd.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Published on: 2025-10-03 05:59:14 - newser.com
Can Galmed Pharmaceuticals Ltd. (GPH) stock withstand sector downturnsSwing Trade & Verified Chart Pattern Trade Signals - newser.com
What drives Galmed Pharmaceuticals Ltd GPH stock priceRelative Strength Index (RSI) & High Yield Trading Growth - earlytimes.in
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):